T3 Companies’s Exagen XGN Stock Holding History

T3 Companies’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-72,000	Closed	-$216K	–	241
2026 Q1	$216K	Buy	72,000 +15,000	+26%	+$58K	0.28%	61
2025 Q4	$347K	Buy	+57,000	New	+$519K	0.43%	48

Other funds holding XGN

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

T3 Companies's XGN Position: Q2 2026 in Review

T3 Companies sold out of Exagen (XGN) in Q2 2026, closing a stake of 72,000 shares — an estimated $216K sold.

T3 Companies first reported a position in XGN in Q4 2025 and held it in 2 quarters. The position peaked at $347K in Q4 2025. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

T3 Companies reported no remaining Exagen position as of Q2 2026 after selling out during the quarter.
T3 Companies sold 72,000 Exagen shares in Q2 2026, an estimated $216K.
T3 Companies first reported a position in Exagen in Q4 2025 and held it in 2 quarters.
T3 Companies's Exagen position peaked at $347K in Q4 2025.
57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on T3 Companies's 13F filing for Q2 2026, filed 27 Jul 2026.